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Chemokine and inflammatory cytokine changes during
chronic wound healing
DAVID P. FIVENSON, MD°; DUYEN T. FARIA, DO°; BRIAN J. NICKOLOFF, MD, PhDb; PETER J. POVERINI, DDS'°;
STEVEN KUNKEL, PhDs; MARIE BURDICK, MV, ROBERTM. STRIETER, MDd
Wound healing is a complex process resulting from an interplay of processes including coagulation, inflammation,
angiogenesis, and epithelialization . The chemokine family hasbeen shown to contain members that are potent regu-
lators of many of thesepathways . Because we have previously shown that chemokines "pool" in biologic wound dress-
ings, we studied the levels of CXC and CC chemokines, along with key inflammatory mediators, serially from a group
of patients undergoing therapy for chronic venous leg ulcers . After8 weeks, all patients had marked clinical healing
of their ulcers (median 63 .3% reduction in size) with two of 10 completely healed . Wound fluids extracted from dress-
ings showed high levels of platelet factor-4 and interferon-y-inducible protein, with a trend toward increases in the
ratio of the sums of the angiogenic versus angiostatic CXC chemokines (p = 0,082) in the tissues collected from the
center of the ulcers during wound closure, Neutrophil-activating peptide-2 and interleukin-8 accounted for the most
changes in wound fluid angiogenic chemokines, with significant differences both as compared with baseline levels
and with patients' plasma level noted at various time points between weeks 0 and 8. The level of angiostatic (cont.)
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chemokines, interferon-y inducible protein 10 and platelet-activating-4, fell most significantly between weeks 0 and3
as compared with plasma levels . The observed shift toward angiogenic CXC chemokines suggests that effective healing
in chronic venous insufficiency ulcers appears to "move" the ulcer bed toward a state more conducive to epithelial-
ization, characteristic of the proliferative phase of wound healing. CC chemokines were also elevated at baseline in
the wound fluid samples as compared with the patients' plasma levels . Macrophage inflammatory protein-1 (3 and
regulated on activation, normal T expressed and secreted (RANTES) levels decreased with healing, whereas there
were significant increases in the tissue levels of monocyte chemoattractant protein-1 and macrophage inflamma-
tory protein-1 a over the first 4 weeks of therapy (p<_ 0.05 for both) . Coincident with these changes was a steady in-
crease in the ratio of interleukin-1 R/interleukin-1 receptor antagonist protein in the ulcer center tissues, which also
correlated with healing (p < 0 .05) as compared with a decreasing ratio at the ulcer edge, and a biphasic response in
the wound fluids . These findings suggest that advanced wound care techniques help move the ulcer from a chronic
inflammatory state into one more characteristic of the late inflammatory/early proliferative phase of wound healing .
Chemokines may play a critical role in the pathogenesis of chronic venous ulcers through their effects on angiogen-
esis and/or the progression of inflammatory reactions at the site of injury. (WOUND REP REG 1997;5:310-22)
Normal wound healing involves the coordinated inter-
play of cells, extracellular matrix, and an ever-expand-
ing host of mediators . The cellular physiology of wound
repair includes the coordinated stimulation ofblood ves-
sel growth (angiogenesis), keratinocyte and fibroblast
proliferation, production of epithelial and endothelial
basement membrane zones, andconnective tissues (e.g .,
collagens, ground substance)." In skin, there are three
well-recognized phases of wound repair: the inflamma-
tory phase, the tissue formation or proliferative phase,
andthe tissue remodeling phase. 1,6 Although these phases
are not necessarily mutually exclusive, they are some-
what distinct andhelp to provide the investigator with a
reasonable approach to understanding normal versus
abnormal wound repair.
Chronic wounds appear to be, at least in part, medi-
ated by dysregulation of cytokines. 1,2 Some investigators
have also suggestedthat the nonhealing state is due to a
disruption of the precise coordination of the temporal
expression of these mediators and not necessarily an
absolute absence of anyparticular one.' One ofthe most
common forms of chronic wounds is the chronic venous
insufficiency ulcer (CVIU). When reviewed in 1985, these
were shown to affect as many as 500,000 patients and
cost the U.S . Health Care System in excess of $250 mil-
lion per year.' Among the potentially important families
of mediators involved in orchestrating effective wound
healing, and targets for dysregulation in the pathogen-
esis of chronic wounds, are the chemokines . 6,8,9
As their name suggests, these factors were originally
described because oftheir principal effects on chemotaxis .
Thechemokines consist of anumber ofdistinct 8- to 10-kd
cytokines that exhibit from 20%to 55% homologyin amino
acid sequence .8All chemokines have fourcysteine residues
that form two disulfide bridges. Members of the CXC
chemokine subfamily are located on chromosome 4, and
share two conserved cysteines separated by one
unconserved amino acid, hence the designation C-X-C. This
family includes interleukin-8 (IL-8), growth-regulated gene
product (GRO(x), platelet basic protein and its cleavage prod-
ucts (connective tissue-activating peptide-III, [CTAP-III]),
R-thromboglobulin (RTG), neutrophil-activating peptide-2
(NAP2); interferon-y-inducible protein (IP10), epithelial neu-
trophil-activating peptide-78 (ENA-78), granulocyte chemo-
tactic protein-2 (GCP2), and monokine-y-interferon-induc-
ible gene (MIG). 8-11 IL-8, ENA-78, NAP2, and GROa all
share a Glu-Leu-Arg (ELR) motif preceding the first cys-
teine in the N-terminus . 8,1° These ELR+ CXC chemokines
have been associated with significant angiogenesis func-
tion in vitro, as well as sharing abilities to stimulate both
keratinocyte proliferation and migration. 11,12 CXC
chemokines-including IP10, MIG, and platelet factor-4
(PF4)-lack this ELR motif (referred to as ELR- CXC
chemokines) and have been shown to be angiostatic .1115
The CC chemokine subfamily of genes are located on
chromosome 17, and have adjacent conserved cysteine
amino acid residues, hence the designation CC. These pro
teins include monocyte chemoattractant proteins 1 to 4
(MCP-1 to -4), macrophage inflammatory protein-la and -
1(3 (MIP-la and MIP-1(3), regulated on activation, normal
T expressedand secreted (RANTES), and1-309. Members
ofthis subfamily were originally describedfor their chemo-
tactic activity on monocytes andmacrophages.8 The effects
of CC chemokines also have been expanded recently to in-
clude T-cell chemotaxis andmitogenesis, fibrogenesis, and
control ofHIV infection. 10,13,16 These chemokines also have
been associated with avariety ofimportant functions with
relevance to woundhealing.a .11,17-2°
In this study, we have investigated the tissue and
wound fluid levels of representative proinflammatory,
anti-inflammatory, and macrophage-related cytokines,




series of patients with CVIU. We report that the
angiostatic chemokines, PF4 and IP10, are abnormally
elevated in both tissues and wound fluids of these pa-
tients at baseline as compared with normal skin levels .
These ELR- chemokines remained elevated throughout
an 8-week observation, but were found to decrease in
relation to the amounts of ELR+ chemokines in associa-
tion with clinical wound healing. We also report that
CVIUs are characterized by aberrantly high levels of the
proinflammatory mediator, IL-1(3 . Healing is shown to
be associated with a shift toward macrophage and anti-
inflammatory cytokine profiles that parallel the progres-
sion to later stages of wound healing. Healingwas asso-
ciated with decreases in IL-1(3, MIP-1(3, and RANTES
along with increases in IL-1 receptor antagonist protein
(IRAP), IL-10, MIP-la, and MCP-1 . These data suggest
that CVIUs may be due to the persistence of a chronic
inflammatory state that prevents the normal progres-
sion of wound healing. Our results suggest that the
chemokines may be important in the pathogenesis of
CVIUs, and a shift in their relative ratios may be an
important part of the change that occurs when a CVIU
begins to heal .
MATERIAL AND METHODS
All patients enrolled in the study gave written and informed
consent to participate under protocols approved by the
Henry Ford Health System Human Rights Committee.
Diagnosis of CVIU was confirmed by
photoplegthymography (< 20 sec) and ankle-brachial in-
dex (> 0.65) . All patients underwentaprophylactic 2-week
course of antibiotics, and local debridementwas performed
with curettage ofundermined edges to remove devitalized
tissues and fibrin before baseline evaluation . Each patient
wasevaluated at baseline, andthen weekly with photogra-
phyand surface area tracings on acetate paper to calculate
woundarea . Each woundwas dressed with astandard regi-
men of a layer of nonadherent dressing, covered by a
hydrofoam pad(Allevyn ; SmithandNephewUnited, Largo,
Fla.) and then wrapped with a graduated compression
dressing bandage of zinc-oxide paste-impregnated gauze.
A 2-mm punch biopsy of normal leg skin (above the knee),
ulcer edge, and ulcer center was obtained at baseline . Re-
peated biopsies at the ulcer edge and center were obtained
at weeks4 and 8, respectively . At baseline (WO) andweekly
for 8 weeks (Wl to W8), the central 2-cm diameter of the
hydrofoamdressing directly overlying the ulcer center was
collected and stored at-70° C for subsequent extraction of
woundfluid.
Specimen preparation
Wound fluid samples were all extracted from Allevyn dress-
ings by homogenization in 2 ml of sample buffer (sterile
phosphate-buffered saline solution [PBS] containing a cock-
tail of 1% phenylmethylsulfonyl fluoride, 0.001% antipain,
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0.001% aprotinin, 0.001% leupeptin, 0.001% pepstatin A)
followed by sonication.15 This technique has been shown
previously to result in recovery of viable quantities of
cytokines. 21 We also performed pilot studies in which puri-
fied chemokines were added to the Allevyn dressing, and
then were successfully reextracted with high recovery
rates. 21 Tissue samples were similarly processed by homog-
enization in 2 ml of sample buffer. All samples were centri-
fuged to remove debris and then filtered through 1.2-gym
filters (Gelman Sciences, Ann Arbor, Mich.) before analy-
sis. Total protein content of each tissue sample was deter-
minedby the Lowrymethod to normalize for differences in
yield between samples.
ELISA quantitation of chemokines and cytokines
IL-8, IP10, ENA-78, GROa, PF4, NAP2, MIP-la, MIP-1(3,
MCP-1, RANTES, IL-10, transforming growth factor-R
(TGF-(3), IL-1(3, IRAP, IL-6, and tumor necrosis factor-a
(TNF-(x) were quantified usingamodification ofa double
ligand ELISA method . 11,18,19 Flat-bottomed 96-well
microtiter plates were coated with 50 VL/well rabbit anti-
cytokine antibodies (Sigma Chemical Co., St . Louis, Mo.)
(1 !tg/ml in 0.6 mol/L NaCl, 0.26 mol/L H,SO,, and0.08 N
NaOH, pH 9 .6, for 16 hours at 4° C), and then washed
with PBS (pH 7.5) containing 0.05% Tween-20 (Sigma)
(wash buffer). Nonspecific binding sites on microtiter
plates were blocked with 2% bovine serum albumin in
PBS and incubated for 90 minutes at 37° C. Plates were
rinsed four times with wash buffer, and samples were
added (50 pl/well) and incubated for 1 hour at 37° C.
Plates were washed four times with wash buffer, and 50
gl/well ofbiotinylated rabbit anticytokine antibodies were
added for 30 minutes at 37° C. They were again washed,
and the chromogen substrate added. Plates were incu-
bated at 25° C, and the reaction terminated with 50 gL/
well of3mol/LH,BO, solution . Results were analyzed at
490 nm in an ELISA reader and sensitivity was consis-
tently 50 pg/ml or less .
Data analysis
All tissue results were represented after correction for
the total protein content. The individual samples were
correlated to the percentage healing determined by the
change in surface area of the weekly acetate tracings .
Spearman's rank correlation coefficients were generated
because the data were not normally distributed. The
mean changes in individual sample sites (ulcer edge, ul-
cer center, and wound fluid extracted from the dress-
ings) over time were analyzed by Student's t test . Tissue
samples were compared between weeks 0 and 4. Mean
changes in wound fluids were analyzed between weeks 0
and 8. Because much of the data also were not normally
distributed, median levels are presented. Baseline mean/
median differences between these sites were also ana-
lyzed by Student's paired t test or Wilcoxon's sign rank
test for data that departed from anormal distribution .
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Table 1. CXC chemokine levels in plasma and wound fluid and tissue extracts from patients with CVIU at the initiation ofthe study
Ratio ELR+/ELR- 8.33 ± 4.90 0.40 ± 0.17
(1 .19) (0 .10)
[NS]
NS, Not significant ; =, indicates significant trend .
'Values indicate mean ± SE .
'Values in parentheses beneath mean ± SE indicate median .
t-Tests were interpreted liberally because of the over-
all modest sample size . Significance was defined as p
<- 0.05, and significant trends were defined as 0 .10 >_ p
> 0.05. Wound fluid levels were compared with tissue
levels and plasma levels for individual cytokines ver-
sus time, the ratio of the sums of ELR+ to ELR-
chemokines and for the ratio of IL-1(3 to IRAP . No
analysis of biologic activity was performed on the re-
covered wound fluid proteins . Therefore, tissue and
plasma values represent a single time point. Wound
fluid levels represent 7-day accumulations each, less
any loss caused by proteolytic degradation.
Sample source
0.35±0.13 0.30±0.16 3 .54±3 .06
(0 .20) (0 .26) (0 .14)
[NS] [0.0311
$All tissue results are expressed as ng/ml/mg total protein recovered after extraction of a 2-mm punch biopsy in 2 ml of buffer. Patient plasma and
chronic wound fluid samples are expressed in ng/ml . Chronic wound fluids represent the total amount of cytokine that accumulated in the wound
dressing over a 7-day period o£ time and then extracted into 2 ml of buffer.
"Italic values in brackets beneath mean ± SE in this column indicate significance level of this value versus normal skin.
'Italic values in brackets beneath mean ± SE in this column indicate significance level of this mean versus plasma .
RESULTS
Fourteen patients were evaluated at baseline ; with 10 of
these followed weekly for 8 weeks. Size of the leg ulcers
in these patients ranged from 2.0 to 85.4 cm2, with amean
surface area of 26.5 ± 6.6 cm2 . Measurement of the ul-
cers at week 8 indicatedarange offrom completely healed
(n = 2) to 50.8 cm2, with a mean size of 12.4 ± 3.7 cm2 .
This equated to a mean 46 .8 ± 17.5% (median = 63.3%)
reduction in ulcer surface area over the 8-week study in
these 10 patients . After 6 months, (n = 5) two additional
patients hadhealed, andthe remaining three hadamean
ulcer area of 7 .8 cm2.
Chemokine Normal skin** Ulcer center Ulcer edge Plasma Wound fluid
IP10 185.3 ± 43.8 83.8 ± 25 .9 113.3±24.7 1.64±0.81 1 .24±0.48
(210 .2)' (74.1) (127 .2) (0 .60) (0 .51)
[0.018]" [0.008]" [0.029]§
PF4 4416 ± 2168 35348± 13218 28794± 8335 60792 ±12670 7280± 2827
(2046) (17313) (26174) (66549) (796 .7)
[0 .016] [0 .058]° [0 .017]
Sum ELR- 4601± 2168 35432± 134229 28907± 8353 37393 ± 11421 7281± 2827
(2192) (17321) (26358) (48811) (797)
[0.016] [0.058]= [0 .0011
IL-8 0.68 ± 0.45 14.76 ± 7.55 7.14 ± 2.84 0.23 ± 0.12 55.30 ± 17.30
(0) (3 .73) (4.35) (0) (38.48)
[NS] [0.069]= [0 .031]
ENA-78 0 5.88 ± 4.00 2.55 ± 1.71 0.77 ± 0.66 4.34 ± 1.88
(0) (0) (0) (0) (1 .47)
[NS] [NS] [NS]
NAP2 5873± 1619 2547± 1111 3713 ± 836.7 19274± 3897 97.82 ± 24.02
(6269) (1157) (3779) (20381) (65.07)
[NS] [0.077]` [0 .016]
GROa 58 .5 ± 21.1 7.61 ± 4.23 16 .6 ± 8.52 63.9 ± 57 .3 113.0 ± 11.04
(52.0) (1 .35) (1 .05) (5 .85) (0 .53)
[0 .057]= [NS] [NS]
Sum ELR+ 5933± 1634 2575± 1108 3740± 837 11901± 3566 270.4 ± 126.4
(6373) (1159) (3782) (9615) (132 .7)




Table 2. CC chemokine and proinflammatory cytokine levels in plasma and wound and tissue extracts from patients with CVIU at the
initiation of the study
ND, Not done ; NS, not significant ; =, indicates significant trend.
"Values indicate mean ± SE .
'Values in parentheses beneath mean ± SE indicate median .
CXCchemokines in the untreated CVIU (baseline)
In all samples, NAP2 was the ELR+ CXC chemokine in
highesttissue content, andPF4wasthe highestELR-CXC
chemokine (Table 1) . The prominent PF4 content in nor-
Sample source
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$All tissue results are expressed as ng/mI/mg total protein recovered after extraction ofa 2-mm punch biopsy in 2 ml of buffer. Patient plasma and chronic
wound fluid samples are expressed in ng/ml. Chronic wound fluids represent the total amount of cytokine that accumulated in the wound dressing over
a 7-day period of time and then extracted into 2 ml of buffer.
-Italic values in brackets beneath mean ± SE in this column indicate significance level of this value versus normal skin.
'Italic values in brackets beneath mean ± SE in this column indicate significance level of this mean versus plasma.
mal skin wasunexpected, because platelet activation (the
major source ofPF4) is not acharacteristic ofnormal skin."
At baseline, all CVIUs were characterized by much
higher levels of PF4 and IP10 as compared with IL-8,
Cytokine Normal skin** Ulcer center Ulcer edge Plasma Wound fluid
IL-10 0 1 .27 ± 1.23 ND 0 145.9 ± 140.5
(0)$ (0) (0) (0 .07)
[NS]" [NS)§
TNF-a 0.31+0.31 0.59 ± 0.46 ND 1.94 ± 1.66 0.24 ± 0.07
(0) (0) (0) (0 .14)
[NS] [0.038]
IL-6 0 17.10 ± 8.97 ND 4.45 ± 3.07 2.08 ± 0.90
(0) (0) (0) (0 .44)
[0 .089] = [NS]
TGF-(3 6.33 ± 6.33 7.50 ± 5.27 1.89 ± 1 .89 28.80 ± 16.25 0.07 ± 0.05
(0) (0) (0) (6 .60) (0)
[NS] [NS]" [0.0311
MCP-1 0 0.53 ± 0.23 0.51±0.20 0 0.15±0.04
(0) (0 .15) (0 .22) (0) (0 .06)
[0 .0611_ [0.033] [NS]
MIP-1a 0.08+0.08 0.36 ± 0.09 0.28 ± 0.12 0 19.00 ± 18.30
(0) (0 .44) (0 .20) (0) (0 .06)
[0 .085] = [NS] [NS]
MIP-1a 0 0.14 ± 0.06 0.098 ± 0.064 0 16.04 ± 12.37
(0) (0) (0) (0) (0 .14)
[0.05] [NS] [NS]
RANTES 0 3.70 ± 3.16 2.51 ± 1 .93 7754± 7206 0.73 ± 0.49
(0) (0) (0) (558 .2) (0 .15)
[NS] [NS] [0.003]
IL-lp 0.08 ± 0.08 21.89 ± 21.03 2.09 ± 0.89 0.03 ± 0.02 5.21 ± 3.98
(0) (0 .61) (1 .0) (0) (0 .76)
[0.0311 [0.0081 [0.0551 =
IRAP 22.48 ± 5.02 8.48 ± 3.11 14.24 ± 3.62 6.26 ± 3.03 22.76 ± 17.85
(17.58) (4.02) (16.17) (1 .60) (2 .32)
[0.032] [0.083]= [NS]
IL-la/IRAP 0.08 ± 0.08 0.84 ± 0.29 1.79±0.59 0.01±0.01 0.31±0.16
(0) (0 .77) (1 .23) (0) (0 .06)
[0.074]= [0 .016] [NS]
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Figure 1 ELR+/ELR- ratios as function of healing during CVIU treatment . Ratio of aggregate sum of
ELR+/ELR- chemokines ((IL-8 + NAP2 + ENA-78 + GRO(x) /(PF4 + IP10)) in samples from patients with
CVIUs compared with percentage wound closure . A, Dot plot of individual wound fluid ELR+/
ELR- ratios as function of healing during CVIU treatment . Wound fluids extracted from central
portion of overlying hydrofoam dressing show biphasic ratio with wound closure . Many values
overlap, giving appearance offewer data points at each time point . W 1 and W7 each had one
data point that was off scale . B, Individual tissue ELR+/ELR- ratios as function of healing. Ulcer
center versus ulcer edge ELR+/ELR- CXC chemokine ratios show increasing ratio in ulcer center
as compared with stabilizing ratio at ulcer edge . Many values overlap, giving appearance of
fewer data points at each time point . Solid lines at each time point, median value; dashedlines,
mean value (n = 10) .
376 FIVENSONETAL .
Figure 2 Median individual CXC chemokine levels in wound fluids as function of healing during
CVIU treatment . Median values of each ELR+ CXC chemokine (IL-8, NAP2, ENA-78, and GRO(x)
in samples from patients with CVIUs compared with percentage wound closure . IL-8, NAP2,
and GROa levels steadily increased throughout 8-week observation period (n = 10) .
GROa, NAP2, and ENA-78 (Table 1) . To study their ag-
gregate effects, thesum ofthe protein levels for theELR+,
ELR-, and ratio of ELR+/ELR-chemokines were calcu-
lated for each sample . As shown in Table 1, the ELR+/
ELR- ratio at baseline between ulcer sites was not sta-
tistically significant (p = 0.16) . None of the chemokines
showed statistically different levels between the ulcer
edge versus ulcer center at baseline . The median ratio
in the subjects' normal skin at baseline was 1.90, whereas
plasma from CVIU patients and healthy controls (data
not shown) had a median ELR+/ELR- ratio of approxi-
mately 0.50. Table 1 summarizes these baseline findings .
Only GROa levels in the ulcer center showed a signifi-
cant trend versus normal skin at baseline, whereas both
PF4and IP10 were significant versus normal skin. Com-
parison betweenthe ulcer edges and normal skin showed
significant trends for all CXC values except GROoc and
ENA-78 . In the wound fluids at baseline, IP10, PF4,
NAP2,IL-8 andthe sums of ELR+ andELR- chemokines
and their ratio, were all found to be significantly differ-
ent compared with normal plasma .
CXC chemokine changes during the initiation of
wound healing in CVIUs
Over the 8-week observation period, there were promi-
nent changes in the ELR+/ELR- ratio detected in the
wound fluid and tissue samples, which were associated
with the percentage of healing. In Figure 1, the changes
in ELR+/ELR- ratio are compared with healing in the
wound fluids (Figure 1,A), the ulcer center, and the ul-
cer edge (Figure 1,B) . Here, there appears to be a com-
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partmental effect that is associated with woundclosure.
At the wound margins, there is a stabilization in the
ELR+/ELR- ratio in association with the decreasing sur-
face area ofthe ulcer, whereasthewound centers showed
a steady increase in this ratio.
At the end of the 8-week observation period, only
changes in wound fluid IL-8 levels showed a significant
trend (p = 0.09) ; however, several of the CXC chemokine
levels were significantly different as compared with
baseline during this time (Figure 2) . In particular, NAP2
changes over weeks 2 to 5 were significantly different
from baseline (p<- 0.05), whereas changes in IL-8 (weeks
2to 4, 8) were showing significant trends (0.1 >>-p >0.05)
(Figure 2) . Neither IP10 or PF4, nor their sum, was sig-
nificantly changed at anytime pointwhen compared with
baseline levels .
However, when compared with each patient's
plasma at baseline, there were significant differences
noted during the 8 weeks of observation for IP10
(weeks 0 to 7), PF4 (weeks 0 to 3 and 6), the ELR-
sum (weeks 0to 8, p <- 0.05), IL-8 (weeks 0 to 2, 7, and 8),
NAP2 (weeks 0, and 2 to 4), and GROa (weeks 1 to 3)
(Figure 2) . The absolute changes in tissue levels between
week 0 and 4 for IP10 (p = 0.071), NAP2 (p = 0.079), and
the ELR+ sum (p = 0.080) were also found to have a
significant trend in the ulcer edge samples, whereas
only the NAP2 (p = 0.060) and ELR+ sum (p = 0 .067)
changes approached a significant trend for the same
period from the ulcer center samples.
Thus, each chemokine appears to have a unique ex-
pression profile during the wound healing process. In-
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Figure 3 Wound fluid IL-10 levels as function of healing during CVIU treatment, Wound dress-
ing samples collected from patients observed over 8-week period . Median percentage heal-
ing compared with individual detectable levels of IL- 10 after normalization for total protein in
all samples . Gradual but insignificant increase in IL-10 level noted after approximately 10%
healing (week 3), which continued throughout observation time . Many values overlap, giv-
ing appearance of fewer data points at each time point . Solid lines at each time point,
median value; dashed lines, mean value (n = 10)
creases in IL-8, GROoc, and NAP2, combined with de-
creases in IP10 and PF4, resulted in a net increase of
ELR+ chemokine levels as the wounds started to close.
Rigorous statistical analysis revealed statistically sig-
nificant correlation onlybetween the percentage ofwound
closure and decreases in PF4 and the total ELR- (p <-
0.05 for each) from the ulcer center samples. Theincreas-
ing ratio of ELR+/ELR-found in the ulcer center showed
a significant trend in correlation with the degree ofwound
closure (p = 0.08), whereas none ofthe other trends noted
for these mediators in either the edge skin or wound
dressings was significant in relation to healing.
In normal skin, there were also fluctuating levels
ofthese mediators during the healing process, suggest-
ing that there are systemic effects attributable to the
wound healing process. Healing ofthe CVIUs at a dis-
tal site was associated with atrend toward significance
with the decreases in normal skin levels of IL-8, NAP2,
and the sum of the ELR+ chemokines between weeks
0 and 4 (p = 0.07, 0.08, and 0.08, respectively) .
Inflammatory cytokine levels in the untreated CVIU
Baseline levels ofthe CC chemokines MCP-1, MIP-la,
MIP-lß, and RANTES, along with nonchemokine
cytokines important in the initiation and regulation




ß, and TNF-(x), are summarized in Table 2. Elevated
IL-6 levels were shown to have a trend toward signifi-
cance in the ulcer centers as compared with normal
skin (p = 0.089), whereas IL-6 levels were variable in
the edge samples and in the wound fluids . IL-6 was
the only cytokine that showed a significant trend in
the differences between baseline levels in ulcer center
versus edge tissue samples (p = 0.089). TNF-oc levels
in the baseline samples from the dressings were sig-
nificantly elevated (p <_ 0 .05), but were generally un-
detectable in the small tissue biopsies analyzed . IL-
10 levels also were found to vary widely and were very
high in some of the dressing samples at baseline (mean
WO IL-10 in wound fluid level = 145 .9 ± 140.5, median
= 0 .069; Figure 3), whereas they were barely detect-
able in tissue samples. TGF-ß levels in wound fluids
were lower than expected based on other reports of
the role of TGF-ß in wound healing,'' with only the
wound fluid levels of TGF-ß being significantly el-
evated in comparison with the patients' normal plasma
levels at baseline (p <- 0.05) .
IL-lß levels were higher at baseline in ulcer tis-
sues and wound fluid samples (Table 2 and Figures 4,
A and 4, B) as compared with normal skin or plasma .
The ulcer edge and center differences were significant
(p <- 0.05 for both, Figure 4, B), whereas wound fluid
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Figure 4 Median IL-lß/TRAP ratio as function of healing during CVIU treatment . A, Dot plot of
individual wound fluid IL-lß/IRAP ratios as function of healing during CVIU treatment. Dressing
extracts show biphasic response as compared with wound closure throughout 8-week observa-
tion period . B, Individual tissue IL-1 ß/IRAP ratios as function of healing . Gradual increase in ulcer
center levels seen, as compared with steady decreases in levels of ratio in ulcer edge over 4-
week observation period . Many values overlap, giving appearance offewerdata points ateach
time point. Solid lines at each time point, median value, dashed lines, mean value (n = 10) .
levels showed a significant trend (p = 0.055) . The natu-
ral inhibitor of IL-1, IRAP, had a significant trend to-
ward lower levels at baseline only in the tissues, as com-
pared with normal skin or plasma. When the ratio of
IL-lß/IRAP was used to compare the balance between
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these pro- and anti-inflammatory mediators, it was sig-
nificantly elevated in the ulcer edge and center, but not
in the wound fluid samples, as compared with normal
skin and plasma at baseline (edge, p = 0.016 ; center, p =
0.074 ; wound fluid, p = 0.338; Table 2) .
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Cytokine trends during CVIU treatment
Changes in IL-6 levels in the ulcer edges between
baseline and week 4 also showed a significant trend (p
= 0.062). The wound fluid IL-10 levels gradually in-
creased after week 3 (11 .2% median healing, Figure
3) ; however, none of these changes was significant with
respect to baseline . Normal skin TGF-R levels in-
creased by week 4 (data not shown), whereas changes
throughout the study period were negligible for ulcer
edges, ulcer centers, and wound fluid levels (Table 2) .
TNF-a and IL-1(3 were always significantly different
from baseline plasma levels . The IL-1(3/IRAP ratio
appeared to follow a biphasic response profile in the
wound fluids when compared with healing (Figure 4,
A) and was significantly different from its baseline
value from weeks 2 to 7 (p <- 0.05) . The IL-1(3/IRAP
ratio showed a significant increase from the ulcer cen-
ter tissues and was statistically correlated with the
degree of wound closure (Figure 4, B ; p <_ 0 .05) . This
ratio declined between baseline and week 4 in the ul-
cer edges, butthese changes were not significantly as-
sociated with healing (Figure 4, B) .
CC chemokine levels at baseline and throughout
the wound healing process
At baseline, MCP-1, MIP-la, and MIP-1P in both tis-
sue and wound fluid were elevated in comparison with
normal skin and plasma levels (Table 2) . MIP-1(3 de-
clined during the healing process until approximately
week 4 and showed a subsequent rise toward the end
ofthe observation (results not shown) . During the heal-
ing process, there was a slight increase in MCP-1
within the tissues (results not shown) . Only the rise
in MIP-la in the ulcer center (between weeks 0 and 4)
was significant (p<- 0.05), and only the changes in nor-
mal skin MCP-1 levels correlated with wound closure
(p <_ 0.05) . Thus, the more potent macrophage
chemoattractants (MCP-1 and MIP-la) followed a
trend toward gradual increases in ulcer levels during
healing; whereas, the reverse was seen for MIP-1(3,
which predominantly affects T cells .
Wound fluids extracted from dressing samples
showed no significant trends for the CC chemokines
over the 8-week study period when compared with
baseline levels . RANTES was significantly higher at
baseline only in woundfluid samples (p<- 0.05) as com-
pared with tissue or plasma levels, but it also trended
toward lower levels with wound closure. When the
wound fluid levels of the CC chemokines were com-
pared with plasma levels, individual expression pro-
files were evident, as seen with the CXC chemokines .
Of note were changes in RANTES, which was always
significantly different (p <- 0 .005) from plasma levels .
Significant differences were also seen in MIP-la
(weeks 1 and 3 to 8), and MIP-1(3 (weeks 1, 5, and 8)





In this study, we have investigated tissue and wound
fluid levels of the recently characterized family of
chemoattractants, the chemokines, in a controlled series
ofpatients with CVIUswhowere all treated with a stan-
dardized compression dressing . The CC chemokine sub-
family principally has its effects on mononuclear cell func-
tion and would be predicted as important in the mid-
and later-phases of wound healing; whereas, the CXC
chemokine subfamily primarily affects neutrophils and
lymphocytes, with both angiogenic and angiostatic pro-
teins characterized. However, as with most cytokines,
both subfamilies also include multifunctional members,
with effects reported on virtually every cell type in the
wound repair response . 6,8,11,20 We describe a dynamic
cytokine profile that may help to provide insight into the
pathogenesis of CVIUs.
We have found that baseline CVIUs are character-
ized by a CXC chemokine phenotype that overwhelm-
ingly favors the antiangiogenic effects of PF4 and IP10,
the so-called ELR- chemokines . The predominant
ELR- chemokine in untreated CVIUs was PF4,
whereas the predominantELR+ chemokine was NAP2 .
These findings were the same as those for the patients'
normal skin and plasma, as well as for the relative
levels reported for CXC chemokines in normal human
plasma and bronchoalveolar-lavage fluids ." Chronic
wound fluids from these patients had a mean baseline
PF4 level 14-fold higher than that seen in normal hu-
man plasma and almost 77-fold that of normal
bronchoalveolar-lavage fluid. 8,1°,11 It was particularly in-
teresting to find relatively high levels of PF4 in the pa-
tients' normal skin (mean = 4416 ± 2158 ng/ml/mg; me-
dian = 2046) in relation to either their plasma (mean =
60,762 ± 12,670 ng/ml; median = 66,549) or normal hu-
man plasma (mean = 4425 ± 616.9 ng/ml), because plate-
let activation (the primary source of PF4) was not ex-
pected to be an important event in normal skin .14 Thus,
systemic upregulation of CXC expression appears to be
present, despite the local nature of the CVIU . Wound
fluid results represent the 7-day accumulation of mate-
rial in the dressing. Because no assessment of the sta-
bility of the chemokines in this environment for 7 days
wasmade, it is possible that significant levels ofcytokines
are not represented in these wound fluid values .
The patients' normal skin samples had a median of
210.2 ng/ml of IP10 as compared with the untreated
CVIUs, which ranged from 0.51 ng/mUmg in the wound
fluids to 74.1 ng/mUmg in the ulcer centers and 127.2
ng/mUmgin the ulcer edges. This was also an unexpected
paradox, because this interferon-y(IFN-y) inducible pro-
tein would have been expected to be higher in the in-
flamed, nonhealing CVIU center and much lower in nor-
mal skin (which is relatively devoid of activated T cells
producing IFN-y22 ). IFN-y has been shown previously to




cell growth, having been used effectively for the treat-
ment of keloids and hemangiomas.23,211
Chronic wounds are characterized by a polymorphic
infiltrate of leukocytes, predominated by lymphocytes
andneutrophils and a relative paucity of macrophages.22
This histopathology is analogous to many acute andsub-
acute inflammatory processes. We found that the only
ELR+ CXC chemokine present in levels higher than in
normal skin in the untreated CVIU was IL-8; the other
CXC chemokines were all higher in the patients' normal
skin. Although no direct measures of angiogenesis were
performed in this series of patients with CVIU, angio-
genesis is predicted to have been inhibited by the over-
whelming levels of ELR- chemokines, despite IL-8
upregulation in the untreated ulcers . IL-8 is a potent,
proinflammatory chemoattractant for neutrophils and T
cells and is known to be increased in chronic wounds . 2,4,7
Healing was associated with a relative shift in the ratio
of ELR+ to ELR- chemokines; yet the overall
antiangiogenic effects of PF4 and IP10 predominated,
as is the case in normal human plasma . Among the indi-
vidual chemokines, there was an early peak in IL-8 lev-
els that was followed by progressive increases in NAP2
and GROa. Again, this followed our hypothetical model
with the proinflammatory mediators, which may be fa-
cilitating the infiltration ofT cells and neutrophils, coin-
cident with the resolution of inflammation and the ini-
tiation of wound closure.
Trends seen in the tissue levels of CXC chemokines
were not statistically significant in comparison with the
percentage of wound closure; thus their direct role in
wound healing is only speculative. The differential
change in the ELR+/ELR- ratio between the ulcer edge
and center, a stable ratio at the ulcer edge, and an in-
creasing ratio in the ulcer center paralleling wound heal-
ing, appears to follow the physiology of the healing
chronic wound. Increased need for vascularity and an-
giogenesis characterizes the changes in the poorly healed
central portion of the wound, whereas a decreasing re-
quirement for angiogenesis at the margins of the
wound allows for epithelial migration. 5,6 IP10 has been
shown to stimulant keratinocyte growth 11,24,21 ; and
overexpression of its inducer, IFN-y, has been impli-
cated in the hyperproliferative state seen in psoria-
SiS . 25,26 Thus, local increases in IP10 at the ulcer edge
may help stimulate keratinocytes to divide and mi-
grate, along with a down regulatory effect on angio-
genesis. Antiangiogenic effects are best known clini-
cally for the interferons through their use in the
treatment of childhood hemangiomas. 21,28
Another interesting findingwas that there appeared
to be a coincident decrease in the levels ofNAP2 and IL-
8 (p = 0.083, and 0.07, respectively) in the normal skin
collected sequentially from patients in this clinical trial.
This, along with the increases in PF4 found in these pa-
tients' plasma and normal skin described previously,
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further support that the induction of wound healing
within CVIUs may be more than a local phenomenon,
because significant shifts in the distribution of inflam-
matory mediators occur throughout the cutaneous and
vascular compartments .
In untreated CVIUs, we found there was a slight el-
evation ofall 4 CC chemokines studied, both within the
ulcer tissue and in the wound fluids . MIP-la, MIP-1p,
MCP-1, andRANTES are all chemotactic for Tcells and
have recently been associated with chronic T-cell medi-
ated inflammatory disorders, including rheumatoid ar-
thritis, pulmonary fibrosis, and chronic nonprogressive
HIVinfection.8,16," Although no significant changes were
detected in association with healing, there was a trend
for levels of MIP-1p and RANTES to fall, analogous to
the decreases in the other proinflammatory cytokines
described previously . These wounds also appeared to
have atrendtoward increasing levels of MCPA and MIP-
la (the more potent macrophage chemotaxis) in associa-
tion with healing. 2° Thus, a parallel shift in mediators
from a proinflammatory state to one of inflammation
resolution was seen between these four CC chemokines
and the shifts observed between the angiogenic and
angiostatic CXC chemokines in CVIUs during therapy.
Elevated levels ofIL-1(3 andIL-6 in baseline CVVUswere
demonstrated to decrease as healing began. As wound clo-
sure proceeded throughout the 8-week trial, there was an
inverse change in the ratio of IL-1P to its inhibitor, IRAP,
particularly in the tissues from the ulcer center (p<- 0.05) .
Thus, just as the angiostatic CXCchemokines decrease with
the initiation of therapy in CVIU, so too do the relative
levels of IL-1(3 . We suggest that these ratios maybe one of
the more sensitive immunologic parameters ofhealing and
the concurrent resolution ofthe chronic inflammatory state
present in CVVUs.
Resolution of inflammation is also represented as be-
ing coordinated with healing by the changes seen in the
levels ofIL-10 during the healing process, with a rise noted
in the first 4 to 5 weeks in conjunction with progression
toward healing. Although not statistically significant, it is
interesting that most of the IL-10 detected was recovered
from the wound fluids and not from tissue samples. Pre-
liminary data 29 suggest that these high levels of IL-10 in
chronic wound fluid may not be functional, andthat some
breakdownproductmay account for the variable levels de-
tected by ELISAin some patients .
These changes in the pro- and anti-inflammatory
cytokines and chemokines all point toward a shift in the
dynamics of the CVIU occurring during the induction of
wound healing. This shift moves from a chronic, pro-in-
flammatory state characterized by high levels of TNF-a,
II-1p, IIr6, IL-8, RANTES, andMIP-1p (all known for their
effects on the earlier components of the pathway), toward
one characterized by increases in anti-inflammatory
cytokines that stimulate resolution ofinflammation by re-
cruiting mononuclear phagocytes, favoring angiogenesis,
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and inducing keratinocyte migration and fibrogenesis . In-
creases in IRAP and IL-10 directly shut down the
proinflammatory effects of IL-1(3, IL-2, and IFNy. 30,31
Interpreting these changes suggests that the inhibi-
tion of healing may be related to early constituents of
the inflammatory process (e.g ., polymorphonuclear leu-
kocytes, lymphocytes) and mediated by imbalances in the
levels of some of these cytokines . Therapy is associated
with decreases in some ofthese inflammatory mediators,
along with increases in those mediators that favor pro-
gression toward the characteristics typical of the prolif-
erative and maturation phases of wound repair . Our
study shows that increasing monocyte and macrophage
cytokines, whose job it is to "mop up" inflammatory re-
actions, allows progression toward wound closure . In-
creasing levels of some ofthese inflammatory mediators
(e.g., IL-10, MCP-1, TGF-(3, IRAP, IP10) also may have
roles in initiating the proliferation of fibroblasts and
keratinocytes, which are necessary for wound closure and
remodeling . 1,2,24,30,32
The lush granulation tissue that characterizes the nor-
mal healing wound is principally the result of cytokine-
induced vessel proliferation and must occur before epithe-
lial migration .5,32 A global shift toward the proangiogenic
effect ofincreased ELR+ chemokines is seen, along with a
compartmental change that reflects the cellular dynamics
within the CVIUs studied . As the wound begins to heal,
and effective granulation tissue is laid down, the inflam-
matory state changes to one characteristic of the prolifera-
tive (i .e ., macrophage and fibroblast dominated) stage of
healing . Keratinocytes begin to migrate in from the wound
edges, and the stimulus for angiogenesis is shut down (as
evidenced by the stabilization in relative levels of ELR-
chemokines at the ulcer edges during therapy) . Those me-
diators that augment macrophage, fibroblast, and
keratinocyte functions predominate .s
The hypothesis we propose is that the causes ofCVIUs
are probably multifactorial, but their principal feature,
the inability of these wounds to heal, appears to be re-
lated to the persistence ofthe chronic inflammatory state
combined with a relative lack of angiogenesis . Dynamic
changes are presented that show these ulcers will heal
with appropriate compression dressing therapy and
wound care . Healing is shown to be characterized by a
change from the chronic pro-inflammatory state to one
of resolving inflammation and increasing cytogenesis,
which parallels an increase in the relative levels of an-
giogenic chemokines within the nonhealing portions of
these ulcers .
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